Etorikoksib: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 1:
{{Short description|COX-2 selective NSAID medication}}
{{Use dmy dates|date=March 2024}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443748261
| IUPAC_name = 5-kloro-6'-metil-3-[4-(metilsulfonil)fenil]-2,3'-bipiridina
| image = Etoricoxib.svg
| alt =
<!-- Clinical data -->
| tradename =
| Drugs.com = {{drugs.com|international|etoricoxib}}
| pregnancy_AU = C
| pregnancy_AU_comment =
| pregnancy_category = Tidak direkomendasikan
| routes_of_administration = Oral
| ATC_prefix = M01
| ATC_suffix = AH05
| legal_AU = S4
| legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines-2017 | access-date=30 March 2024}}</ref>
| legal_BR = C1
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=31 March 2023 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=3 August 2023 |access-date=16 August 2023 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=4 April 2023}}</ref>
| legal_UK = POM
<!-- Pharmacokinetic data -->
| bioavailability = 100%
| protein_bound = 92%
| metabolism = [[Hati]], [[Sitokrom P450|CYP]] terlibat secara luas (terutama CYP3A4)
| elimination_half-life = 22 jam
| excretion = [[Ginjal]] (70%) & feses (20%)
<!-- Identifiers -->
| IUPHAR_ligand = 2896
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 202409-33-4
| PubChem = 123619
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01628
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 110209
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = WRX4NFY03R
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03710
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 6339
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 416146
<!-- Chemical data -->
| C=18 | H=15 | Cl=1 | N=2 | O=2 | S=1
| smiles = O=S(=O)(c3ccc(c2cc(Cl)cnc2c1cnc(cc1)C)cc3)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MNJVRJDLRVPLFE-UHFFFAOYSA-N
}}
'''Etorikoksib''' adalah obat penghambat COX-2 selektif yang dikembangkan dan dikomersialkan oleh [[Merck & Co.]]. Obat ini disetujui di 63 negara di seluruh dunia pada tahun 2007, kecuali Amerika Serikat di mana [[badan Pengawas Obat dan Makanan Amerika Serikat]] (FDA) mengirimkan Surat Tidak Dapat Disetujui kepada Merck dan meminta mereka untuk memberikan data tambahan.<ref>{{Cite web |title=Merck & Co., Inc. (Jobs) Receives Non Approvable Letter from FDA for Arcoxia (etoricoxib) |url=https://www.biospace.com/article/merck-and-co-inc-a-href-http-www-biospace-com-jobs-public-viewcompanyprofile-aspx-company_id-248338-font-color-red-jobs-font-a-receives/ |access-date=15 October 2023 |website=BioSpace |language=en-US}}</ref> Obat ini dipatenkan pada tahun 1996 dan disetujui untuk penggunaan medis pada tahun 2002.<ref name=Fis2006>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=978-3-527-60749-5 |page=522 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA522 |language=en}}</ref>
| |||